Skip to main navigation
Go back to homepage
  • About Us
    • Overview
    • Our Values
    • Leadership
    • Board of Directors
  • Focus
    • Overview
    • PAH & PH-ILD
    • Inhaled Treprostinil
  • Pipeline & Products
    • Our Pipeline
    • L606
    • Clinical Trials
    • Commercial Products
    • Publications
  • Technology
    • Overview
    • PRINT
  • Patients
  • Medical Professionals
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Analyst Coverage
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
    • Corporate Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • SEC Filings
    • IR Resources
      • Investor FAQs
      • IR Contact
      • Email Alerts
      • Proxy Online
  • Careers
    • Overview
    • Our Values
    • Employee Benefits
    • Career Opportunities

Publications

Pioneers in rare cardiopulmonary disease

Explore the science behind our clinical trials.

Search

March 5, 2025
| Publication
Hall, S., Ravichandran, V., Patel, S., Gwyn, G.
The Evolution of Inhaled Therapies: Advancements in Respiratory Disease Management. Respiratory Therapy: The Journal of Pulmonary Technique. 2025; 20(2)
October 9, 2024
| Poster
Habib, N., Ravichandran, V., Feldman, J., Patel, S., Gwyn, G., Galloway, A., Saggar, R.
Baseline characteristics of patients enrolled in the ASCENT study: Evaluating safety and tolerability of YUTREPIA, a dry-powder inhaled treprostinil in pulmonary hypertension. CHEST Annual Meeting
Boston, MA
June 29, 2024
| Poster
Lavon, B., Backer J., Patel, S., Ravichandran, V., Gwyn, G., Saggar, R.
High-Resolution Computed Tomography (HRCT) chest scans to examine the association between regional drug deposition of LIQ861 (YUTREPIA™) and vasodilation in PH-ILD population. World Symposia on Pulmonary Hypertension (WSPH)
Barcelona
June 29, 2024
| Poster
Patel, S., Galloway, A., Gwyn, G., Saggar, R.
The ASCENT Study: An Open-Label Prospective Multicenter Study to Evaluate Safety and Tolerability of DPI LIQ861 (YUTREPIA) in Pulmonary Hypertension. World Symposia on Pulmonary Hypertension (WSPH)
Barcelona
May 22, 2024
| Poster
Habib, N., Restrepo, R., Trivieri, M., Shapiro, S., Burger, C., Patel, S., Galloway, A., Kan, P., Saggar, R.
An Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD. 2024 American Thoracic Society International Conference
San Diego, CA
February 2, 2024
| Poster
Tully, J., Saggar, R., Prabel, J., Garcia, A., Patel, S., Chen, K., Kan, P.
Clinical Pharmacokinetics of an Extended-Release Formulation of Inhaled Liposomal Treprostinil (L606) to Reduce Dosing Frequency. Pulmonary Vascular Research Institute (PVRI) 2024 Annual Congress
London
May 22, 2023
| Poster
Burger, C.D., Sahay, S., Patel, S., Galloway, A., MacLennan, D., Elwing, M.
Exploratory Efficacy Analysis of INSPIRE Open-Label Extension Study With Inhaled Treprostinil (YUTREPIA™). American Thoracic Society International Conference
Washington D.C.
October 18, 2022
| Poster
Simon, M., Shapiro, S., Sahay, S., et al
Clinical Outcomes of YUTREPIA™ Dose in 6MWD and Quality of Life. CHEST 2022 Annual Meeting
Nashville, TN
October 18, 2022
| Poster
Patel, S., Prabel, J., MacLennan, D., Rosen, G
Robustness of YUTREPIA™, a Dry-Powder Inhaled Formulation of Treprostinil, in Patient Misuse Scenarios. CHEST 2022 Annual Meeting
Nashville, TN
July 26, 2022
| Publication
Hill N.S., et al.
INSPIRE: Safety and Tolerability of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (PAH). Pulmonary Circulation;2022 Jul 26; doi.org/10.1002/pul2.12119
  • First page «
  • Previous page ‹
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • …
  • Next page ›
  • Last page »
Go back to homepage

Socials

  • Science
    • Pipeline & Products
    • Technology
    • Publications
  • Company
    • About
    • Leadership
    • Board of Directors
    • Careers
    • Contact
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Corporate Governance
    • Corporate Social Responsibility
    • Financial Information

Copyright © 2026 Liquidia Corporation. All Rights Reserved.

  • Accessibility
  • Cookie Policy
  • Legal
  • Privacy Policy